Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT7208 in Healthy Participants and Adult Patients With Multiple Sclerosis
NCT07085507Phase 2Recruiting
- Sponsor
- Vidya Therapeutics
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VT7208 in multiple sclerosis (MS) (6 arms), sponsored by Vidya Therapeutics. Primary endpoint: Incidence, nature, and severity of treatment emergent adverse events and serious adverse events at 16 weeks. Started Aug 2025; status: recruiting.
02
Drugs
VT7208
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07085507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085507.